Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.

Published

Journal Article

Androgen deprivation therapy (ADT) targeting the androgen receptor (AR) is a standard therapeutic regimen for treating prostate cancer. However, most tumors progress to metastatic castration-resistant prostate cancer after ADT. We identified the type 1, 2, and 4 collagen-binding protein transforming growth factor-β (TGFβ)-induced protein (TGFBI) as an important factor in the epithelial-to-mesenchymal transition (EMT) and malignant progression of prostate cancer. In prostate cancer cell lines, AR signaling stimulated the activity of the transcription factor SPDEF, which repressed the expression of TGFBI ADT, AR antagonism, or overexpression of TGFBI inhibited the activity of SPDEF and enhanced the proliferation rates of prostate cancer cells. Knockdown of TGFBI suppressed migration and proliferation in cultured cells and reduced prostate tumor growth and brain and bone metastasis in xenograft models, extending the survival of tumor-bearing mice. Analysis of prostate tissue samples collected before and after ADT from the same patients showed that ADT reduced the nuclear abundance of SPDEF and increased the production of TGFBI. Our findings suggest that induction of TGFBI promotes prostate cancer growth and metastasis and can be caused by dysregulation or therapeutic inhibition of AR signaling.

Full Text

Duke Authors

Cited Authors

  • Chen, W-Y; Tsai, Y-C; Yeh, H-L; Suau, F; Jiang, K-C; Shao, A-N; Huang, J; Liu, Y-N

Published Date

  • August 15, 2017

Published In

Volume / Issue

  • 10 / 492

PubMed ID

  • 28811384

Pubmed Central ID

  • 28811384

Electronic International Standard Serial Number (EISSN)

  • 1937-9145

International Standard Serial Number (ISSN)

  • 1945-0877

Digital Object Identifier (DOI)

  • 10.1126/scisignal.aam6826

Language

  • eng